From mucosal infection to successful cancer immunotherapy

Anne‐Gaëlle Goubet; Mathieu Rouanne; Lisa Derosa; Guido Guido Kroemer; Laurence Zitvogel

doi:10.1038/s41585-023-00784-5

Related publications

Article2018

The hallmarks of successful anticancer immunotherapy

Lorenzo Galluzzi, Timothy A. Chan, Guido Guido Kroemer, Jedd D. Wolchok, Alejandro López‐Soto

Article2004

The site of infection and ethnicity of the patient influence the biological pathways to HPV-induced mucosal cancer

Wei Li, Carol H. Thompson, Yvonne E. Cossart, Christopher J. O’Brien, Jihong Liu, Richard A Scolyer, Jonathan Carter, Christopher Dalrymple, Barbara Rose

Article2020

Bronchial mucosal inflammation and illness severity in response to experimental rhinovirus infection in COPD

Jie Zhu, Patrick Mallia, Joseph Footitt, Yusheng Qiu, Simon Message, Tatiana Kebadze, Julia Aniscenko, Peter J Barnes, Ian M. Adcock, Onn Min Kon, Malcolm Johnson, Marco Contoli, L Stanciu, Alberto Papi, Peter K. Jeffery, Sebastian L. Johnston

Article2020

The Contribution of Epigenetics to Cancer Immunotherapy

Lorea Villanueva, Damiana Álvarez‐Errico, Manel Esteller

Article2023

Nodal analysis determined nasal mucosal-associated mediators were associated with accelerated clinical recovery from SARS-CoV-2 infection

Steven P. Cass, Jonathan Baker, Christine Mwasuku, Sanjay Ramakrishnan, Mahdi Mahdi, Peter J Barnes, Louise Donnelly, Richard Russell, Dan V. Nicolau, Rocío T. Martínez-Nuñez, Mona Bafadhel